Patient-reported influences on COVID-19 vaccine acceptance and hesitancy in people with hidradenitis suppurativa.

Https://doi.org/10.1093/bjd/ljad166 Dear Editor, COVID-19 continues to pose a risk to patients with hidradenitis suppurativa (HS) due to the high prevalence of comorbidities associated with severe COVID-19 disease.[1] Although vaccination is an effective primary defence against adverse outcomes, global COVID-19 vaccine uptake is approximately 69%.[2] Limited data exist on the attitudes of patients with HS toward the COVID-19 vaccine. COVID-19 vaccine-hesitant respondents ( I n i = 11/47; 23%) were significantly less likely than vaccine acceptors ( I n i = 635/1233; 51.5%) to report having a close relative or friend who had severe COVID-19 infection ( I P i < 0.001) (Figure 1). Compared with COVID-19 vaccine-accepting respondents ( I n i = 554/1276; 43.4%), COVID-19 vaccine-hesitant respondents ( I n i = 24/47; 51%) more frequently reported being "dissatisfied" or "very dissatisfied" with their HS care on a 5-point Likert scale ( I P i = 0.01), and significantly more often declined influenza vaccination [ I n i = 434/1276 (34.0%) vs. I n i = 25/47 (53%); I P i < 0.01)]. [Extracted from the article]